AIM ImmunoTech Inc.
AIMAMEXHealthcare● Active
$0.52
+$0.00(+0.60%)
Market Cap$1766097
P/E Ratio—
52W High$19.73812
52W Low$0.21
AIM ImmunoTech Inc. (AIM) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · AIM · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.09M | $0.17M | $0.20M | $0.14M | $0.14M |
| Cost of Revenue | $0.34M | $0.03M | $0.04M | $0.00M | $0.85M |
| Gross Profit | ($0.25M) | $0.14M | $0.16M | $0.14M | ($0.71M) |
| Gross Margin %(computed) | -284.09% | 81.76% | 79.21% | 100.00% | -529.63% |
| Operating Expenses | |||||
| R&D Expenses | $3.92M | $6.20M | $10.93M | $6.99M | $7.67M |
| G&A Expenses | $7.70M | $13.71M | $21.14M | $13.07M | $8.67M |
| Total Operating Expenses | $10.28M | $19.91M | $32.08M | $20.06M | $18.12M |
| Operating Income | ($10.53M) | ($19.77M) | ($31.92M) | ($19.92M) | ($18.84M) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $3.18M | $5.19M | $1.07M | $0.63M | $0.00M |
| Interest Expense | $0.81M | $0.58M | $0.00M | $0.00M | $0.07M |
| Income Before Tax | ($13.96M) | ($17.32M) | ($28.96M) | ($19.45M) | ($19.13M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($13.96M) | ($17.32M) | ($28.96M) | ($19.45M) | ($19.13M) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-8.62 | $-11.22 | $-21.64 | $-14.69 | $-14.67 |
| Wtd Avg Shares | 1.62M | 1.54M | 1.34M | 1.32M | 1.31M |
| EBITDA | ($10.32M) | ($16.49M) | ($28.72M) | ($19.87M) | ($18.29M) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more AIM ImmunoTech Inc. data
About AIM ImmunoTech Inc. (AIM) Income Statement
AIM ImmunoTech Inc. (AIM) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, AIM reported revenue of $0.00B, gross profit of ($0.00B) (gross margin -284.09%), and net income of ($0.01B) — a net profit margin of -15861.36%.
Frequently asked questions
AIM · 4 questionsAIM ImmunoTech Inc. (AIM) reported revenue of $0.00B for 2025, down 48.2% year-over-year.
AIM revenueAIM salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08